NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma

Hepatocellular carcinoma presents strong sexual dimorphism, being two to three times more frequent in males than in females; however, the role of sex in response to immunotherapies in HCC remains unknown. We demonstrate that NOTCH1, an understudied oncogene in HCC, elicits sexually dimorphic antitumor immunity and response to FDA-approved immunotherapies. Surprisingly, males harboring NOTCH1-driven tumors displayed enhanced antitumor immune responses, which, in mice, were mediated by dendritic and T cells. Conversely, females harboring NOTCH1-driven tumors presented immune evasion and resistance to immunotherapies through a defect in dendritic cell (DC)-mediated priming and activation of CD8+ T cells in mice, which was restored therapeutically with CD40 agonism. Mechanistically, the sexually dimorphic immunity was mediated by genes in the sex chromosomes but not by sex hormones. Together, our study unravels an unexpected association between NOTCH1 and sex in cancer immunity and highlights the potential of restoring the DC-CD8+ T-cell axis with CD40 agonism to improve outcomes. Significance: Although HCC presents strong sexual dimorphism, the role of sex in response to immunotherapies remains elusive. With a novel HCC mouse model and validation in patients with HCC, we demonstrate that NOTCH1 disrupts antitumor immunity specifically in females through a mechanism mediated by sex chromosome genes, which is reversed with CD40 agonism. See related commentary by Zhu and Koltsova, p. 452.

Authors

Institutions

Publication Details

Journal
Cancer Discovery
Published
2024-11-19
DOI
https://doi.org/10.1158/2159-8290.cd-24-1215
Citations
8
Primary Topic
Cancer-related molecular mechanisms research
Type
article
Field-Weighted Citation Impact
2.28

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma

Ian Liebling, Maxime Dhainaut, Alice O. Kamphorst, Takahiro Kodama et al.
8 citations
Cancer Discovery
Cancer-related molecular mechanisms research
2.28
article

NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma

Ian Liebling, Maxime Dhainaut, Alice O. Kamphorst, Takahiro Kodama, Marina Ruiz de Galarreta, Nesteene J. Param, Sarah Cappuyns, Anthony Lozano, Katherine E. Lindblad, Bruno Giotti, Alexander M. Tsankov, Amaia Lujambio, Marina Bárcena‐Varela, Romain Donné, Yulei Wang
article en
8 citations

Abstract

Hepatocellular carcinoma presents strong sexual dimorphism, being two to three times more frequent in males than in females; however, the role of sex in response to immunotherapies in HCC remains unknown. We demonstrate that NOTCH1, an understudied oncogene in HCC, elicits sexually dimorphic antitumor immunity and response to FDA-approved immunotherapies. Surprisingly, males harboring NOTCH1-driven tumors displayed enhanced antitumor immune responses, which, in mice, were mediated by dendritic and T cells. Conversely, females harboring NOTCH1-driven tumors presented immune evasion and resistance to immunotherapies through a defect in dendritic cell (DC)-mediated priming and activation of CD8+ T cells in mice, which was restored therapeutically with CD40 agonism. Mechanistically, the sexually dimorphic immunity was mediated by genes in the sex chromosomes but not by sex hormones. Together, our study unravels an unexpected association between NOTCH1 and sex in cancer immunity and highlights the potential of restoring the DC-CD8+ T-cell axis with CD40 agonism to improve outcomes. Significance: Although HCC presents strong sexual dimorphism, the role of sex in response to immunotherapies remains elusive. With a novel HCC mouse model and validation in patients with HCC, we demonstrate that NOTCH1 disrupts antitumor immunity specifically in females through a mechanism mediated by sex chromosome genes, which is reversed with CD40 agonism. See related commentary by Zhu and Koltsova, p. 452.

Cancer DiscoveryVol. 15(3)
Osaka Gakuin University (JP), Gene Therapy Laboratory (FR), Tisch Hospital (US), The University of Osaka (JP), Icahn School of Medicine at Mount Sinai (US), KU Leuven (BE)
Damon Runyon Cancer Research Foundation, Belgian American Educational Foundation, Fundación Alfonso Martín Escudero, Fundación Ramón Areces, Asociación Española para el Estudio del Hígado, Japan Agency for Medical Research and Development, Cholangiocarcinoma Foundation, Philippe Foundation, Fonds Wetenschappelijk Onderzoek, National Cancer Institute
Good health and well-being
Openalex Percentile: Top 11%
Cancer-related molecular mechanisms research
2.28
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.